Teprotumumab for Thyroid-Associated Ophthalmopathy

Overview of attention for article published in New England Journal of Medicine, May 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

news: 71 news outlets
blogs: 7 blogs
policy: 1 policy source
twitter: 110 X users
patent: 25 patents

facebook: 9 Facebook pages
wikipedia: 1 Wikipedia page
googleplus: 2 Google+ users
f1000: 1 research highlight platform
guideline: 4 clinical guideline sources

Readers on

mendeley: 416 Mendeley

So far, Altmetric has seen 10 public wall posts from 9 users.

Farmacologia_FMABC_News, 18 Dec 2019

Teprotumumab for Thyroid-Associated Ophthalmopathy https://www.nejm.org/doi/full/10.1056/NEJMoa1614949

Graves' Disease and Thyroid Foundation, 02 Nov 2019

New treatment for Graves Opthalmopathy is a game changer and can prevent long standing proptosis in patients with Grave disease.

Graves' Disease and Thyroid Foundation, 14 Nov 2017

We previously shared an abstract from the New England Journal of Medicine on Teprotumumab, a drug currently in a Phase 3 trial…

ต้อง ตรวจ ต่อม, 08 Jun 2017

"ยาเทโพ" ช่วงนี้ยาพวก monoclonal antibody กำลังมาแรง เมื่อซักต้นเดือนก่อนอ่าน NEJM เจอยาตัวหนึ่งชื่อ Teprotumumab อ่านตอนแรกๆรู…

This page shows the most recent Facebook posts that mention this research output. Click here to find out how to access more activity, including 6 additional Facebook posts.